# Suppression of ERalpha in Hematopoietic Stem Cell-Derived Adipocytes Increases Adiposity via Kynurenine and the Aryl Hydrocarbon Receptor

> **NIH NIH U54** · UNIVERSITY OF COLORADO DENVER · 2023 · $468,500

## Abstract

The menopausal transition, an unavoidable aging-related phenomenon in women, is accompanied by
increased abdominal adiposity and the concomitant incidence of adipose-related comorbidities, but the
underlying mechanisms remain uncertain. Project 3 of the University of Colorado Specialized Center of Research
Excellence on Sex Differences (SCORE) is based on the premise that alterations in the cellular composition of
adipose tissue are responsible for the shift in body fat distribution and worsening metabolic health observed after
menopause. We previously discovered a novel lineage of adipocytes in the major white adipose depots of mice
and humans generated from hematopoietic stem cells rather than conventional mesenchymal precursors. In
mice, these hematopoietic stem cell-derived adipocytes (HSCDAs) were detected in greater numbers in
abdominal fat depots, suggesting a critical role in influencing metabolic health. Furthermore, estrogen receptor
alpha (ERa) knockdown or ovariectomy significantly increased HSCDA production.
 Recently, two laboratories have presented evidence that diet-induced obesity requires the interaction
between the metabolic intermediate, kynurenine (Kyn) and the aryl hydrocarbon receptor (AhR). Preliminary
data from the Klemm laboratory shows that the enzyme that catalyzes kynurenine production, indoleamine
dioxygenase 1 (IDO1) in adipose tissue, and the AhR are expressed at significantly higher levels in HSCDAs
than other adipocyte populations. Thus, we hypothesize that the loss of estrogen signaling via
ER⍺ promotes the production of HSCDAs and their subsequent production of Kyn (via IDO1) and AhR,
which promotes weight gain, increased adiposity, and related metabolic dysfunction. Three specific aims
will address this hypothesis: Aim 1: test whether HSCDA-targeted deletion of IDO1 or AhR will suppress
increases in body weight, adiposity, and other adipose tissue-related endpoints due to knockdown of ERa in
adipocytes (collaboration with Project 2); Aim 2: test whether targeted ablation of HSCDAs decreases Kyn, IDO1
and AhR and prevents changes in body weight, adiposity and other parameters induced by ERa knockdown
(collaboration with Project 2); and Aim 3: test whether suppression of estrogen production in premenopausal
women stimulates HSDCA production and their production of IDO1 and AhR, and is prevented by estrogen
replacement (collaboration with Project 1). Successful completion of these aims will demonstrate that HSCDAs
are a primary intermediate in the regulation of body weight and adiposity influenced by ERa signaling.
Additionally, these studies will demonstrate the potential benefits of targeting kynurenine metabolism in the
context of gonadal aging. Since HSCDAs are produced from hematopoietic rather than mesenchymal progenitor
cells, they offer the opportunity to modulate not only body-wide metabolism, but also adipocyte metabolic
phenotypes associated with changes in sex hormone production.

## Key facts

- **NIH application ID:** 10712611
- **Project number:** 2U54AG062319-11
- **Recipient organization:** UNIVERSITY OF COLORADO DENVER
- **Principal Investigator:** Dwight J Klemm
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $468,500
- **Award type:** 2
- **Project period:** 2012-09-20 → 2028-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10712611

## Citation

> US National Institutes of Health, RePORTER application 10712611, Suppression of ERalpha in Hematopoietic Stem Cell-Derived Adipocytes Increases Adiposity via Kynurenine and the Aryl Hydrocarbon Receptor (2U54AG062319-11). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10712611. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*